share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K:Blueprint Medicinib 公布2024年第二季度业绩并上调了AYVAKIT® /AYVAKYT®(avapritinib)全年收入指引
美股SEC公告 ·  08/01 07:31
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息